Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- Ophthalmological
- Pharmaceuticals
- Therapeutic
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 5621
License Grant
The Licensor hereby grants the exclusive, perpetual, worldwide right to commercialize, manufacture, sell, market, apply, and utilize all of the Licensor's Technology, whether patented or unpatented, for, but only for, the purposes of delivery of antiapoptotic pharmaceuticals and antiapoptotic nutriceuticals, which are specifically part of the Licensee's Technology known as the Designated Use.
License Property
The Licensor is developing and commercializing a cochleate delivery system pursuant to patents, pending patent applications and proprietary and trade secret information. The Licensor's technology is related to neutraceutical neuroprotective therapies for treating neurodegenerative disease such as macular degeneration and Parkinson's disease.
IPSCIO Record ID: 6835
License Grant
Licensor hereby grants the exclusive, perpetual, worldwide right to commercialize, manufacture, sell, market, apply, and utilize all of the Licensor Technology, whether patented or unpatented, for, but only for, the purposes of delivery of antiapoptotic pharmaceuticals and antiapoptotic nutriceuticals, which are specifically part of the Tatton Technology (the Designated Use).
License Property
Licensor is developing and commercializing a cochleate delivery system pursuant to patents, pending patent applications and proprietary and trade secret information (herein the Licensor Technology).
Field of Use
The rights granted apply for the purposes of delivery of antiapoptotic pharmaceuticals and antiapoptotic nutriceuticals. Neutraceutical neuroprotective therapies are for treating neurodegenerative disease such as macular degeneration and Parkinson's disease.
IPSCIO Record ID: 6897
License Grant
Licensor hereby grants Licensee the exclusive worldwide right to commercialize, manufacture, sell, market, apply, and utilize the BDS Technology for, but only for, the purposes of delivery of antiapoptotic pharmaceutical and nutriceutical treatments.
License Property
Licensor is developing and commercializing a cochleate delivery system pursuant to patents, pending patent applications and proprietary and trade secret information (herein the Licensor Technology).
Field of Use
The rights granted apply to the Licensor Technology for the delivery of antiapoptotic pharmaceutical and antiapoptotic nutriceutical treatment for retinal disease and glaucoma.
IPSCIO Record ID: 5406
License Grant
During 2001, the Company entered into agreements with two biotechnology companies which are developing neutraceutical neuroprotective therapies for treating neurodegenerative disease such as macular degeneration and Parkinson’s disease. The CEO/director is affiliated with these companies.
IPSCIO Record ID: 5405
License Grant
In a related party transaction, we have entered into a license agreement with this development-stage biotechnology company to use our delivery technology in connection with their proposed neutraceutical product with potential application for macular degeneration and retinitus pigmentosa, a disease affecting the retina.
Field of Use
The rights granted apply to the medical industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
